This is a mechanism module, not a specific disease. It models the compartment-specific, direction-specific pharmacology characterized by the Streicher lab across a coherent series of mouse studies (PMID:32371496, PMID:37040443, PMID:41031962, PMID:42263270, PMID:38926482). The flagship paper for this module is Bowden et al. 2026 (PMID:41031962, DOI:10.1097/j.pain.0000000000003813), which established the microglial Src arm.
CRITICAL SCOPE CAVEAT (compartment- and context-specificity). The enhancement is specific to the SPINAL CORD. Hsp90 regulates downstream opioid signaling OPPOSITELY in the brain versus the spinal cord: brain or systemic non-selective Hsp90 inhibition BLOCKS opioid antinociception (PMID:42263270, PMID:32701840), and in chemotherapy-induced peripheral neuropathy and cancer-induced bone pain models Hsp90 inhibitors reduced or blocked opioid antinociception (PMID:32701840). The translationally feasible route is therefore selective inhibition of the spinal-cord-active isoforms (Hsp90-beta, Grp94), not non-selective/systemic Hsp90 blockade (PMID:38926482). Do not let a conforming entry overstate this as a generic "Hsp90 inhibition relieves pain" claim.
All evidence is MODEL_ORGANISM (mouse, intrathecal/intracerebroventricular dosing, CRISPR knockdown); the strategy is preclinical. Conforming disorder nodes should substitute the pain-context-specific model but keep the evidence_source as MODEL_ORGANISM until human data exist.
Node term-binding follows module convention (GO/CL terms only; the drug identity CHEBI id lives on the treatment therapeutic_agent). Key conformance / treatment-relevant target: the trigger node "Spinal Hsp90 Chaperone Restraint of MOR Signaling" is where the drug acts (treatment target_mechanisms INHIBITS the restraint); the central effector "ERK-RSK Cascade Activation" is the convergent hub every mechanistic arm (microglial Src and CGRP-neuron PKCbeta) funnels through.
Can spinal-cord-restricted Hsp90 inhibition (selective Hsp90-beta or Grp94 inhibitors delivered systemically) reproduce in humans the opioid dose-reduction and tolerance-rescue seen in mice, without triggering the brain/systemic Hsp90-inhibition effect that blocks opioid antinociception?
KNOWLEDGE GAP
OPEN
gap_hsp90_spinal_translational_selectivity
Attached to:
Spinal Hsp90 Chaperone Restraint of MOR Signaling
Increased Opioid Antinociception and Improved Therapeutic Index
The entire module chain is established in mice with intrathecal or isoform-selective dosing. Because non-selective/systemic Hsp90 inhibition has the opposite (opioid-blocking) effect in the brain and in some cancer-pain models, clinical translation depends on achieving spinal-compartment or spinal-isoform selectivity in humans, which has not yet been demonstrated.
Spinal Hsp90 Chaperone Restraint of MOR Signaling
trigger
The trigger and the drug-target node, named for the biological process that the treatment acts on (following module convention). In the spinal dorsal horn the chaperone Hsp90 normally restrains a downstream mu-opioid receptor (MOR) signaling cascade. Pharmacological Hsp90 inhibition delivered intrathecally (17-AAG/tanespimycin, KU-32) removes this chaperone-imposed brake, enabling the amplified MOR signaling modeled by the downstream nodes. The effect is compartment-specific: inhibiting Hsp90 specifically in the spinal cord enhances opioid antinociception, whereas brain or systemic non-selective inhibition has the opposite, opioid-blocking effect.
Downstream
-
Microglial Src Kinase Activation
-
PKCbeta Activation in CGRP Neurons
Show evidence (4 references)
"Here, we found that inhibiting Hsp90 specifically in the spinal cord enhanced the antinociceptive effects of morphine in mice."
Establishes the trigger of this module: spinal-cord-restricted Hsp90 inhibition enhances morphine antinociception. Evidence source is MODEL_ORGANISM because the effect was measured behaviorally in mice.
"when inhibited in the spinal cord through intrathecal administration of 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) in mice, led to an increase in morphine antinociception"
The flagship paper restates the intrathecal-17-AAG trigger that increases morphine antinociception in mice, the entry point for the Src/microglia mechanism it characterizes.
"regulates downstream opioid signaling oppositely in the brain vs the spinal cord"
Documents the compartment-specificity caveat: the enhancement is confined to the spinal cord and is opposite in direction to brain Hsp90 inhibition, constraining the scope of any conforming claim. Marked PARTIAL because it qualifies rather than fully supports a generic Hsp90-inhibition claim.
+ 1 more reference
Microglial Src Kinase Activation
amplifier
The amplifier arm characterized by the flagship study. Following spinal Hsp90 inhibition, Src-family kinase is upregulated and activated in the spinal dorsal horn, where activated Src colocalizes with microglia. Microglial Src is causally required: microglial-specific Src CRISPR knockdown abolishes the enhanced antinociception, and pharmacological microglial inhibition (minocycline/PLX3397) mimics the Hsp90-inhibition effect while microglial activation (LPS) reverses it. Src acts upstream of ERK in this cascade.
Downstream
-
ERK-RSK Cascade Activation
Show evidence (2 references)
"Immunohistochemistry confirmed the upregulation of Src in the spinal dorsal horn and colocalization of activated Src with microglia."
Localizes the activated Src to the spinal dorsal horn and to microglia, defining the cellular substrate of this amplifier node.
"we used microglial-specific CRISPR knockdown to confirm that microglial Src is essential to the enhanced opioid antinociception observed with spinal Hsp90 inhibition"
Establishes causal necessity of microglial Src via cell-type-selective CRISPR knockdown, the key result of the flagship paper.
PKCbeta Activation in CGRP Neurons
amplifier
A second, parallel amplifier arm established by the same lab with the same cell-type-selective CRISPR logic as the microglial Src arm. Spinal Hsp90 inhibition (with opioid) selectively activates protein kinase C beta (PKCbeta) in calcitonin-gene-related-peptide (CGRP) primary-afferent neurons of the dorsal horn; PKCbeta in these specific cells is required for the enhanced opioid antinociception. Like the Src arm, this contributes to the convergent ERK/downstream MOR signaling enhancement, and it was demonstrated in tail-flick and postsurgical (paw-incision) pain models.
Downstream
-
ERK-RSK Cascade Activation
Show evidence (2 references)
"We then used selective siRNA to identify PKCβ as the active isoform and further found PKCβ to be selectively activated in CGRP neurons by Hsp90 inhibition and morphine combined."
Establishes PKCbeta as the active PKC isoform selectively activated in CGRP neurons by combined Hsp90 inhibition and morphine. Evidence source MODEL_ORGANISM (mouse).
"show that pan-PKC signaling contributes to the enhanced opioid antinociception observed in tail flick and postsurgical pain models"
Ties the PKC arm to the same postsurgical (paw-incision) pain context as the microglial Src arm, supporting it as a parallel amplifier.
ERK-RSK Cascade Activation
central effector
The central effector and convergent hub. Spinal Hsp90 inhibition permits opioid-induced phosphorylation of ERK1/2 and increased abundance of the kinase RSK in the spinal dorsal horn. Mechanistically this convergence is gated by relief of an opioid-induced, AMPK-mediated negative feedback loop (Hsp90 inhibition lowers spinal AMPK, disabling the brake), and microglial Src acts upstream of ERK. Blocking ERK, RSK, or protein synthesis abolishes the enhancement, marking this cascade as the rate-limiting step every mechanistic arm funnels through.
Downstream
-
Enhanced Spinal Mu-Opioid Receptor Antinociceptive Signaling
Show evidence (3 references)
"Hsp90 inhibition enabled opioid-induced phosphorylation of the kinase ERK and increased abundance of the kinase RSK in the dorsal horns of the spinal cord"
Establishes the ERK-RSK cascade as the signaling readout enabled by spinal Hsp90 inhibition, and (with the protein-synthesis/ERK/RSK block experiments) as necessary for the enhancement.
"the underlying mechanism involves the relief of a negative feedback loop mediated by the kinase AMPK"
Identifies relief of an AMPK-mediated negative feedback loop as the mechanism gating ERK activation downstream of Hsp90 inhibition.
"Src is upstream of extracellular signal-regulated kinase in this signaling cascade"
Places microglial Src upstream of ERK, connecting the amplifier node to this central effector.
Enhanced Spinal Mu-Opioid Receptor Antinociceptive Signaling
effector
The effector node. The relieved, amplified cascade downstream of the spinal mu-opioid receptor increases antinociceptive output while the Hsp90-restrained pronociceptive arm is disabled. This enhanced MOR signaling is localized to the spinal cord and is the disorder-agnostic convergence point that translates the molecular cascade into increased analgesic efficacy.
Downstream
-
Increased Opioid Antinociception and Improved Therapeutic Index
Show evidence (2 references)
"In the spinal cord, we have found that Hsp90 inhibition enables antinociceptive signaling and disables pronociceptive signaling to enhance opioid pain relief and reduce side effects."
States the effector logic directly: spinal Hsp90 inhibition enables antinociceptive and disables pronociceptive MOR signaling to enhance opioid pain relief.
"This mechanism downstream of MOR, localized to the spinal cord and repressed by Hsp90, may potentially be used to enhance the efficacy and presumably decrease the side effects of opioid therapy."
Frames the enhanced signaling as a spinal, MOR-downstream mechanism repressed by Hsp90 that can be leveraged to improve opioid efficacy.
Increased Opioid Antinociception and Improved Therapeutic Index
consequence
The consequence node. The enhanced spinal MOR signaling produces increased opioid antinociception at the behavioral level, boosting analgesic potency while reducing and rescuing tolerance and leaving reward and constipation liability largely unchanged, i.e. an improved therapeutic index and an opioid dose-reduction opportunity. Conforming pain-disorder entries substitute the pain-context-specific behavioral model (thermal/tail-flick, incisional/postsurgical, neuropathic, cancer pain).
Show evidence (2 references)
"morphine anti-nociceptive potency was boosted by 1.9-3.5-fold in acute and chronic pain models"
Quantifies the analgesic-potency enhancement produced by spinal Hsp90 inhibition across acute and chronic pain models.
"These results demonstrate that spinal Hsp90 inhibition can improve the therapeutic index of morphine."
States the therapeutic-index improvement (potentiated analgesia with reduced tolerance and unchanged reward/constipation), the disease-relevant consequence of this module.